Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.57 |
| ▸ | CTSB | P07858 | 1/20 | 0.57 |
| ▸ | CTSK | P43235 | 1/20 | 0.57 |
| ▸ | NAAA | Q02083 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.44 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.44 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.44 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.44 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.43 |
| ▸ | PKLR | P30613 | 1/20 | 0.43 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18426023 | 0.87 | GRIN2D (0.52) | CTSLCTSBCTSKNAAAALDH1A1 | |
| SCHEMBL2525766 | 0.87 | GRIN2D (0.52) | CTSLCTSBCTSKNAAAALDH1A1 | |
| SCHEMBL2526379 | 0.87 | GRIN2D (0.52) | CTSLCTSBCTSKNAAAALDH1A1 | |
| SCHEMBL21811404 | 0.85 | CTSL (0.43) | CTSLCTSBCTSKNAAAALDH1A1 | |
| SCHEMBL25296129 | 0.85 | CTSL (0.42) | CTSLCTSBCTSKNAAAHRH3 | |
| SCHEMBL21618373 | 0.85 | NAAA (0.54) | CTSLCTSBCTSKNAAAALDH1A1 | |
| SCHEMBL13519043 | 0.85 | CTSL (0.42) | CTSLCTSBCTSKNAAAGRIN2B | |
| SCHEMBL16422780 | 0.85 | NAAA (0.54) | CTSLCTSBCTSKNAAABCHE | |
| SCHEMBL17274394 | 0.85 | CARM1 (0.44) | CTSLCTSBCTSKNAAAALDH1A1 | |
| SCHEMBL29117236 | 0.85 | CTSL (0.49) | CTSLCTSBCTSKNAAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090186898-A1 | Inhibitors of bruton's tyrosine kinase | ROCHE PALO ALTO LLC | 2009-07-23 | — | — | US | claimed |
| US-10975081-B2 | Substituted fused pyrazole compounds and their use as LRRK2 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-04-13 | — | — | US | disclosed |
| EP-3325449-B1 | HETEROCYCLIC COMPOUNDS, PARTICULARLY PYRIMIDINYLINDAZOLE COMPOUNDS FOR TREATING PARKINSON'S DISEASE | GLAXOSMITHKLINE IP DEV LTD (GB) | 2021-01-13 | — | — | EP | disclosed |
| US-20200079777-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-03-12 | — | — | US | disclosed |
| EP-3464245-A1 | BENZAZEPINE DICARBOXAMIDE COMPOUNDS WITH TERTIARY AMIDE FUNCTION | H. Hoffnabb-La Roche Ag (CH) | 2019-04-10 | — | — | EP | disclosed |
| WO-2017202704-A1 | BENZAZEPINE DICARBOXAMIDE COMPOUNDS WITH TERTIARY AMIDE FUNCTION | F. HOFFMANN-LA ROCHE AG (CH) | 2017-11-30 | — | — | WO | disclosed |
| US-8426441-B2 | Inhibitors of bruton's tyrosine kinase | ROCHE PALO ALTO LLC (US) | 2013-04-23 | — | — | US | disclosed |
| EP-2229390-A1 | NOVEL IMIDAZOÝ1,2-A¨PYRIDINE AND IMIDAZOÝ1,2-B¨PYRIDAZINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2010-09-22 | — | — | EP | disclosed |
| US-20090186898-A1 | Inhibitors of bruton's tyrosine kinase | ROCHE PALO ALTO LLC | 2009-07-23 | — | — | US | disclosed |
| WO-2009077334-A1 | NOVEL IMIDAZO[1,2-A]PYRIDINE AND IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186898-A1 | Inhibitors of bruton's tyrosine kinase | BTK, SYK, LYN | CTSL 4396/4885CTSB 3280/4885CTSK 2184/4885 |
| US-10975081-B2 | Substituted fused pyrazole compounds and their use as LRRK2 inhibitors | LRRK2, PARK7, PINK1 | CTSL 4123/4885CTSB 2293/4885CTSK 968/4885 |
| US-20200079777-A1 | COMPOUNDS | LRRK2, PARK7, PINK1 | CTSL 2196/4885CTSB 605/4885CTSK 354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.